09.04.2013 - A new French start-up secured a seed financing of €32m. Based on an optogenetics/gene therapy approach, it aims to cure eye diseases.
The field of gene therapies is experiencing a serious tailwind these days. On 8 April, GenSight Biologics announced the closure of a €32m Series A financing. The Parisian biopharmaceutical company works on the development of ophthalmic therapeutics – using gene therapy. The financing was co-led by Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
The lead product is expected to enter the clinic in 2013 in LHON patients. The co-founder and CEO of GenSight, Bernard Gilly, explains why ophthalmology is one of the most best indications for gene therapies: "It is promising because of the safety and efficacy demonstrated in certain trials in this field." Other advantages for GenSight are its "unique, proprietary approach to targeting the mitochondria in LHON developed at the Vision Institute in Paris", and – Gilly adds – "the exclusive access to key intellectual property from Novartis for using optogenetics to treat RP patients."
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.